Home » Clinical Trials » Leukemia » NCT04626765
NCT04626765

An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Study Summary

In this study, CAR-T will be administered to children with acute lymphoblastic leukemia to explore the effect of CAR-T intervention time on the duration of complete remission and further verify the long-term safety and efficacy of CAR-T treatment.

Want to learn more about this trial?

Request More Info

Interventions

CD19 CAR-TDRUG
CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
CD22 CAR-TDRUG
CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
CD 19+22DRUG
CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
FludarabineDRUG
25mg/㎡ for D-4、D-3 and D-2
CyclophosphamideDRUG
500mg/㎡ for D-3 and D-2

Study Locations

FacilityCityStateCountry
No.2 Hospital of Hebei Medical UniversityShijiazhuangHebeiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026